PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL), is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Benoit Woessmer, PET Europe CEO at Curium commented, “We are pleased with the growing availability of PYLCLARI® to more nuclear medicine physicians and their patients across Europe.

2024年5月6日，巴黎（环球通讯社）--世界核医学领导者库里姆宣布，今天在德国慕尼黑和纽伦堡，第一批商业剂量的PYLCLARI®已经交付。PYLCLARI®（INN:Piflufolastat（18F），也称为（18F）-DCFPyL），适用于在以下临床环境中用正电子发射断层扫描（PET）检测前列腺癌患者的前列腺特异性膜抗原（PSMA）阳性病变：在初始治疗前对高危前列腺癌患者进行初级分期。在用治愈意图进行初级治疗后，根据血清前列腺特异性抗原（PSA）水平的升高来定位疑似复发患者的前列腺癌复发Curium PET欧洲首席执行官Benoit Woessmer评论道：“我们很高兴PYLCLARI®越来越多地用于欧洲更多的核医学医生及其患者。（笑声）。

With today’s announcement, we are extremely proud to be improving the choice of diagnostic modalities available to our customers in Germany – ultimately for the benefit of patients with prostate cancer.” In Germany, prostate cancer is the most common cancer among men with around 63,400 new cases diagnosed nationwide every year.

随着今天的宣布，我们非常自豪能够改进德国客户对诊断方式的选择，最终为前列腺癌患者带来好处。”在德国，前列腺癌是男性中最常见的癌症，全国每年诊断出约63400例新病例。

Today’s announcement is part of the continued roll-out of PYLCLARI® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, and the Netherlands. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat (18F) Injection) from the Food and Drug Administration (FDA) in May 2021.

今天的宣布是PYLCLARI®在整个欧盟持续推出的一部分，该产品现在可用于希腊、意大利和荷兰的前列腺癌患者。有关PYLCLARI®的更多信息，请访问美国的www.PYLCLARI.com，Lantheus于2021年5月获得美国食品和药物管理局（FDA）对PYLARIFY®（吡氟司他（18F）注射液）的批准。

It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.  A.

它是美国市场上使用最多的PSMA PET试剂。2018年，Curium从Lantheus公司Progenics获得了欧洲权利的许可。